RESTEM to donate its proprietary ULSCs in an approved investigational new drug application phase I clinical study at University of Florida on Polymyositis/Dermatomyositis entitled, “LEVERAGING THE IMMUNOMODULATORY CAPACITY OF MESENCHYMAL STROMAL CELLS FOR THE THERAPY OF REFRACTORY POLYMYOSITIS AND DERMATOMYOSITIS”.
University of Murcia, Spain commences preclinical umbilical cord lining stem cells (ULSCs) animal work on safety, toxicity and biodistribution. University of Murcia will look at safety and toxicity inin vivo animal models. Moreover, they will use a tracking system on the cells to identify where cells travel to following an intravenous infusion in vivo.
University of Murcia, Spain completes preclinical umbilical cord lining stem cells (ULSCs) animal work illustrating safety and no toxic affects following infusion of ULSCs. Moreover, biodistribution clearly illustrates location and migration of ULSCs in animal models.
RESTEM acquires umbilical cord lining stem cells (ULSCs) technology rights in full to include all intellectual property of such, previous studies and any/all research & development previously completed on ULSCs.